You are here
February 8, 2022
Treatment for opioid use disorder in jail reduces risk of return
At a Glance
- Men in a rural jail who received medication to treat opioid use disorder had a reduced likelihood of being arrested or returning to jail or prison after release.
- The results need to be replicated in larger, more diverse populations, but they suggest the promise of drug treatment in helping to reduce reincarceration.
Almost two-thirds of people currently incarcerated in the U.S. have a substance use disorder. Many struggle with opioid addiction. Opioids include prescription pain relievers, heroin, and powerful synthetic versions such as fentanyl that are driving record numbers of overdose deaths.
Medications used to treat opioid use disorder—also called MOUD—can reduce cravings and symptoms of withdrawal. MOUD include buprenorphine, methadone, and naltrexone. However, few jails and prisons offer these evidence-based treatments.
Studies have shown that giving medications for opioid use disorder in jail or prison can reduce the likelihood of a return to opioid use or an overdose after release. Whether drug treatment can also reduce recidivism (reoffending and returning to jail or prison) hasn’t been known.
Researchers led by Drs. Peter Friedmann at Baystate Health Medical Center in Massachusetts and Elizabeth Evans from the University of Massachusetts performed a comparison between two rural jails in the state. The jails were located in adjacent counties with similar rates of recidivism at the start of the study. One, in Franklin County, introduced buprenorphine treatment in 2016. The other, in Hampshire County, didn’t offer the treatment until 2019.
The team compared rates of recidivism between the two facilities for men with opioid use disorder who were released into the community. They tracked the men between 2015 and 2019. The study was funded by NIH’s National Institute on Drug Abuse (NIDA) through the Helping to End Addiction Long-term (HEAL) Initiative. Results were published on February 1, 2022, in Drug and Alcohol Dependence.
Overall, 469 men in the two jails had a diagnosis of opioid use disorder: 197 in Franklin County and 272 in Hampshire County. More than 90% of those in the Franklin County jail received MOUD, most often buprenorphine. In contrast, none of the men in the Hampshire County jail received drug treatment for opioid use disorder.
All men who re-entered their community through mid-2019 were followed for at least one year. During follow-up, fewer than half (48.2%) of men who had been in the jail that offered drug treatment were rearrested or reincarcerated, compared with 62.5% of men released from the jail that didn’t offer MOUD.
This trend held after accounting for other factors that increase the likelihood of recidivism. These included the number of prior arrests and whether people were first arrested as a juvenile or adult. Overall, after adjusting for such factors, men who received MOUD while incarcerated had an estimated 32% lower risk of recidivism.
“Studies like this provide much-needed evidence and momentum for jails and prisons to better enable the treatment, education, and support systems that individuals with an opioid use disorder need to help them recover and prevent reincarceration,” says NIDA director Dr. Nora D. Volkow.
The men included in the study were relatively young and mostly white. The researchers are currently performing further studies of MOUD in both urban and rural jails. These are following more diverse populations, including women and people of color.
- Opioid Overdose Deaths Rise among Black Americans
- High-Dose Buprenorphine for Opioid Withdrawal
- Physician-Pharmacist Collaboration May Improve Care for Opioid Addiction
- Learning About Fatal Opioid Overdoses Changes Prescribing Behavior
- Medications Reduce Risk of Death after Opioid Overdose
- Opioid Overdose Crisis
- Criminal Justice DrugFacts
- NIH HEAL (Helping to End Addiction Long-term) Initiative
- Justice Community Opioid Innovation Network (JCOIN)
References: Recidivism and mortality after in-jail buprenorphine treatment for opioid use disorder. Evans EA, Wilson D, Friedmann PD. Drug Alcohol Depend. 2022 Feb 1;231:109254. doi: 10.1016/j.drugalcdep.2021.109254. Epub 2022 Jan 18. PMID: 35063323.
Funding: NIH’s National Institute on Drug Abuse (NIDA).